Timolol

Timolol (as maleate)

Elevated IOP in patients w/ ocular HTN or open-angle glaucoma.

1 drop in the affected eye(s) bd. Patients can be treated w/ only 1 dose daily in case IOP remains stable at an acceptable level.

Hypersensitivity. Patients w/ reactive airway disease (including bronchial asthma, history of bronchial asthma or severe COPD); sinus bradycardia; sick sinus syndrome, SA block, 2nd or 3rd degree AV block not controlled w/ pacemaker; overt cardiac failure; cardiogenic shock.

Not for inj or ingestion. CV, pulmonary & other adverse reactions seen w/ systemic β-adrenergic blockers may occur. Adequately check cardiac insufficiency before treatment initiation. Reports of resp reactions, including death due to bronchospasm, in patients w/ asthma. May mask signs & symptoms of acute hypoglycaemia; induce dryness of eyes; potentiate certain symptoms of muscle weakness consistent w/ certain myasthenic symptoms; mask signs of hyperthyroidism. Risk of choroidal detachment. Patients w/ CV diseases (eg, CHD, Prinzmetal's angina, cardiac failure) & hypotension; 1st degree heart block; severe peripheral circulatory disturbance/disorders; cerebrovascular insufficiency; mild/moderate COPD; corneal diseases; history of atopy or history of severe anaphylactic reaction. Patients subject to spontaneous hypoglycaemia or w/ labile diabetes. Not recommended to use 2 topical β-adrenergic blockers. May block systemic β-agonist effects eg, of adrenaline. Use in combination w/ a miotic when reducing elevated IOP in angle-closure glaucoma. Contains benzalkonium Cl. Remove contact lenses before instillation & wait at least 15 min before reinsertion. Administer at least 5 min apart if >1 eye prep is being used. Keep eyelid closed for 2 min & close lachrymal duct w/ finger for 2 min after instillation to reduce systemic resorption. May impair ability to drive or operate machinery. Safety & efficacy in patients w/ hepatic & renal impairment have not been established. Pregnancy & lactation. Neonates, infants & younger childn.

Blurred vision, eye pain, eye irritation (eg, burning sensation, irritating sensation, itching, tears, redness), ocular hyperaemia, ocular discomfort.

Mydriasis w/ adrenaline. Potential for additive effects resulting in hypotension &/or marked bradycardia w/ oral Ca channel blockers, β-adrenergic blockers, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine, catecholamine-depleting drugs (eg, reserpine). Possible AV conduction disturbances, left ventricular failure, & hypotension w/ oral or IV Ca antagonists. Simultaneous use of β-adrenergic blockers & digitalis w/ diltiazem or verapamil may have an additive effect in prolonging AV conduction time. Potentiated systemic β-blockade w/ CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Potential additive effect on IOP & known systemic effects of β-adrenergic blockade w/ oral β-adrenergic blockers. Enhanced rebound effect of HTN when stopping administration of clonidine. Decreased response to adrenaline. Increased hypoglycaemic effects of insulin or oral antidiabetics. Regularly monitor IOP w/ concomitant systemic or topical steroids. Caution w/ psychotropic adrenergics.

Antiglaucoma Preparations

S01ED01 - timolol ; Belongs to the class of beta blocking agents. Used in the treatment of glaucoma.

P₁S₁S₃